<DOC>
	<DOC>NCT00980746</DOC>
	<brief_summary>The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with painful diabetic neuropathy.</brief_summary>
	<brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Written informed consent to participate in the study Men and women aged 18 years or older Diagnosis of diabetes mellitus Type 1 or 2 Diagnosis of pain attributed to diabetic neuropathy for more than 1 year prior to enrolment Stable glycemic control: (total glycated haemoglobin [HbA1c] level â‰¤ 11% at screening) Cooperation and willingness to complete all aspects of the study Completion of at least 4 daily diaries during the week preceding randomisation A minimum average daily pain score of 4 on the Numeric rating pain scale (NRPS) in the last 4 diary entries before randomisation. Pain of other origin that might confound the assessment of neuropathic pain of diabetic origin Significant or unstable medical or psychiatric disorders Drug or alcohol abuse in the preceding 2 years Peripheral vascular disease with a history of amputation, except amputation of toes Severe renal function impairment, as shown by calculated creatinine clearance values &lt; 30 mL/min at screening Relevant clinical laboratory abnormalities (e.g., Na+ &lt;130 mmol/L, alanine (ALT) or aspartate (AST) transaminases &gt;2.0 times the upper limit of normal, white blood cell count (WBC) &lt;2,500 cells/mm3) Previous participation in any study with eslicarbazepine acetate Pregnancy or breast feeding History of hypersensitivity to the investigational products or to drugs with a similar chemical structure History of noncompliance Likelihood of requiring treatment during the study period with drugs or other interventions not permitted by the clinical study protocol. Participation in a clinical study within 3 months prior to screening Any clinically significant concomitant condition, which might influence the assessments or conduct of the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pain diabetes neuropathy</keyword>
</DOC>